{"title":"Gut-specific histamine 3 receptor signaling orchestrates microglia-dependent resolution of peripheral inflammation.","authors":"Kerstin Dürholz,Leona Ehnes,Mathias Linnerbauer,Eva Schmid,Heike Danzer,Michael Hinzpeter-Schmidt,Lena Lößlein,Lena Amend,Michael Frech,Vugar Azizov,Fabian Schälter,Arne Gessner,Sébastien Lucas,Till-Robin Lesker,R Verena Taudte,Jörg Hofmann,Felix Beyer,Hadar Bootz-Maoz,Yasmin Reich,Hadar Romano,Daniele Mauro,Ruth Beckervordersandforth,Maja Skov Kragsnaes,Torkell Ellingsen,Wei Xiang,Aiden Haghikia,Cezmi A Akdis,Francesco Ciccia,Tobias Bäuerle,Kerstin Sarter,Till Strowig,Nissan Yissachar,Georg Schett,Veit Rothhammer,Mario M Zaiss","doi":"10.1172/jci184697","DOIUrl":null,"url":null,"abstract":"Chronic inflammatory diseases, like rheumatoid arthritis (RA) have been described to cause central nervous system (CNS) activation. Less is known about environmental factors that enable the CNS to suppress peripheral inflammation in RA. Here, we identified gut microbiota-derived histamine as such factor. We show that low levels of histamine activate the enteric nervous system, increase inhibitory neurotransmitter concentrations in the spinal cord and restore homeostatic microglia, thereby reducing inflammation in the joints. Selective histamine 3 receptor (H3R) signaling in the intestine is critical for this effect, as systemic and intrathecal application did not show effects. Microglia depletion or pharmacological silencing of local nerve fibers impaired oral H3R agonist-induced pro-resolving effects on arthritis. Moreover, therapeutic supplementation of the short-chain fatty acid (SCFA) propionate identified one way to expand local intestinal histamine concentrations in mice and humans. Thus, we define a gut-CNS-joint axis pathway where microbiota-derived histamine initiates the resolution of arthritis via the CNS.","PeriodicalId":520097,"journal":{"name":"The Journal of Clinical Investigation","volume":"694 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of Clinical Investigation","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1172/jci184697","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Chronic inflammatory diseases, like rheumatoid arthritis (RA) have been described to cause central nervous system (CNS) activation. Less is known about environmental factors that enable the CNS to suppress peripheral inflammation in RA. Here, we identified gut microbiota-derived histamine as such factor. We show that low levels of histamine activate the enteric nervous system, increase inhibitory neurotransmitter concentrations in the spinal cord and restore homeostatic microglia, thereby reducing inflammation in the joints. Selective histamine 3 receptor (H3R) signaling in the intestine is critical for this effect, as systemic and intrathecal application did not show effects. Microglia depletion or pharmacological silencing of local nerve fibers impaired oral H3R agonist-induced pro-resolving effects on arthritis. Moreover, therapeutic supplementation of the short-chain fatty acid (SCFA) propionate identified one way to expand local intestinal histamine concentrations in mice and humans. Thus, we define a gut-CNS-joint axis pathway where microbiota-derived histamine initiates the resolution of arthritis via the CNS.